Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells.
Monoclonal antibody-based therapy is one of the most successful strategies for treatment of cancer. However, the insufficient cell killing activity of monoclonal antibodies limits their therapeutic potential. These limitations can be overcome by the application of immunotoxins, which consist of a monoclonal antibody that specifically delivers a toxin into the cancer cell. An ideal immunotoxin combines the functionality of the monoclonal antibody (antagonistic binding to targeted receptors and interaction with the innate immune system) with the cell-killing activity of the toxic moiety. In addition, it should be sensitive for certain triterpenoid saponins that are known to lead to a tremendous augmentation of the antitumoral efficacy of the immunotoxin. In this study, the monoclonal antibodies trastuzumab (Herceptin) and cetuximab (Erbitux) were conjugated via cleavable disulfide bonds to the plant derived toxin saporin. The ability of the modified tumor-specific therapeutic antibodies to deliver their toxic payload into the target cells was investigated by impedance-based real-time viability assays and confocal live cell imaging. We further provide evidence that the immunotoxins retained their ability to trigger antibody-dependent cell-mediated cytotoxicity. They specifically bound to their target cell receptor, and their cell-killing activity was drastically augmented in the presence of triterpenoid saponins. Further mechanistic studies indicated a specific saponin-mediated endo/lysosomal release of the toxin moiety. These results open a promising avenue to overcome the present limitations of therapeutic antibodies and to achieve a higher antitumoral efficacy in cancer therapy.
Institut für Laboratoriumsmedizin, Klinische Chemie und Pathobiochemie, Charité-Universitätsmedizin Berlin , Campus Benjamin Franklin, Hindenburgdamm 30, D-12200 Berlin, Germany.
Roger
R
Gilabert-Oriol
Mayank
M
Thakur
Benedicta
B
von Mallinckrodt
Thomas
T
Hug
Burkhard
B
Wiesner
Jenny
J
Eichhorst
Matthias F
MF
Melzig
Hendrik
H
Fuchs
Alexander
A
Weng
D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D000068818:Cetuximab; D006801:Humans; D000922:Immunotoxins / Q000737:chemistry; D054789:Ribosome Inactivating Proteins, Type 1 / Q000737:chemistry; D012503:Saponins / Q000737:chemistry; D000076985:Saporins; D000068878:Trastuzumab; D014315:Triterpenes / Q000737:chemistry
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000922:Immunotoxins; D054789:Ribosome Inactivating Proteins, Type 1; D012503:Saponins; D014315:Triterpenes; D000076985:Saporins; D000068878:Trastuzumab; D000068818:Cetuximab